According to Bloomberg.com, Esperion Therapeutics, Inc. (NASDAQ: ESPR) has received an average “Hold” rating from eight brokerages that follow the company. For the company, the stock has received a sell recommendation from two analysts, a hold recommendation from two analysts, and a buy recommendation from two analysts. The stock’s average price, according to brokers who have updated their coverage in the last year, is $10.43.
Professionals recently talked about how they felt about the ESPR stock. StockNews.com upgraded the shares of Esperion Therapeutics from “sell” to “hold” on November 3. On Tuesday, August 9, Cowen dropped their price target for shares of Esperion Therapeutics from $15.00 to $13.00 in a research report. On November 2, Morgan Stanley raised their target price for Esperion Therapeutics shares from $7.00 to $9.00 while downgrading the stock to “underweight.”
The opening price of the ESPR stock on Wednesday was $7.44. The stock has a market cap of $548.21 million, a P/E ratio of -1.63, a beta of 0.22, and its 50-day and 200-day moving averages are $7.54 and $6.89, respectively. Over the previous year, Esperion Therapeutics’ prices ranged from $3.28 to $8.85.
Institutional investors and hedge funds have recently bought and sold ESPR shares. Metropolitan Life Insurance Company of New York increased its holdings in Esperion Therapeutics by 71.1% during the third quarter. Metropolitan Life Insurance Co. of New York purchased an additional 1,675 shares of the biopharmaceutical company’s stock during the most recent quarter for a total of 4,032 shares at $27,000.Amalgamated Bank made a $34,000 new investment in Esperion Therapeutics shares during the first quarter. During the second quarter, FMR LLC increased its holdings in Esperion Therapeutics by 30.0%. During the second quarter, Venture Visionary Partners LLC grew its holding in Esperion Therapeutics by $50,000. For a total of 8,669 shares in the biopharmaceutical firm, worth $55,000, FMR LLC purchased an additional 2,003 shares in the most recent quarter. Finally, during the first quarter, Principal Financial Group Inc. made a $49,000 investment in new Esperion Therapeutics shares. Institutions own an astounding 94.63% of the company’s stock.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and sells drugs to treat people with high levels of low-density lipoprotein cholesterol. The tablets NEXLETOL (bempedoic acid) and NEXLIZET are the company’s main product possibilities for treating patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia (bempedoic acid and ezetimibe).
The post Analysts Give Esperion Therapeutics, Inc. (NASDAQ:ESPR) a Consensus Rating of “Hold” appeared first on Best Stocks.
